Introduction
Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene give rise to tumors in a variety of organs including the kidney and the central nervous system. These tumors are a result of inactivation of the wild-type (WT) allele in individuals that are heterozygous for a germ line mutation in VHL. pVHL regulates the hypoxia inducible transcription factors HIF-1a and -2a by acting as an E3 ubiquitin ligase, targeting both proteins for degradation under normal oxygen conditions. Hence, inactivation of pVHL leads to upregulation of both HIF-1a, -2a and the transcription of their target genes (reviewed by Kaelin, 2002) . It remains unknown how exactly loss of pVHL promotes tumor growth. Studies have shown that inactivation of pVHL did not increase tumor formation in vivo (Mack et al., 2003 (Mack et al., , 2005 .
In order to develop effective therapy to treat VHL disease, it is important to identify the contribution of HIF-1a and vascular endothelial growth factor (VEGF) to the angiogenesis and growth of tumors lacking pVHL. Angiogenesis is a result of the balance between proangiogenic and antiangiogenic factors which are released by the tumor and surrounding cells and is therefore highly dependent on the microenvironment (Bergers and Benjamin, 2003) One of the limitations of the subcutaneous tumor implantation model is that the interaction between the malignant cells and the natural stromal microenvironment cannot be recapitulated adequately which may explain the lack of the drastic vascular phenotype associated with loss of pVHL in this model.
We addressed this obstacle by analysing different parameters associated with tumor angiogenesis in a murine astrocytoma implantation model in which transformed astrocytes containing deletions in respectively, pVHL alone (VHL KO) or in combination with HIF-1a (HIF-1a/VHL KO) or VEGF (VEGF/VHL KO) were implanted subcutaneously and in the brain of immunocompromized mice. This allows comparisons of tumor growth derived from the same cell line in different microenvironments, and was shown to successfully recapitulate the relevant host-tumor cell interactions during tumorigenesis in the orthotopic setting (Blouw et al., 2003) .
We report that the VHL KO tumors grow independently of HIF-1a, and that HIF-1a contribution to tumor vascularization depends on the microenvironment in which the cells are grown. Loss of VEGF in the VHL KO background causes a striking reduction in tumor vascularity and angiogenesis, but this only correlates with a reduction in tumor growth when these cells are grown subcutaneously, and not in the brain. Our data indicates that VEGF is a critical factor for tumor angiogenesis, but not for tumor growth associated with loss of VHL.
Results
The subcutaneous tumor growth and vascularization of VHL KO astrocytes is independent of HIF-1a Transformed astrocytes lacking pVHL alone or in combination with HIF-1a were created via the transformation of primary astrocytes isolated from transgenic mice homozygous for specific exons flanked by LoxP sites in the VHL and HIF-1a gene (VHL þ f þ f and HIF1a
, as described in Materials and methods. Taq Man real-time polymerase chain reaction analysis showed over 95% deletion efficiency of the exons (Supplementary Figure 1A) . Functional loss of VHL alone or in combination with HIF-1a was confirmed by a HIF-1a Western blot and by the expression of its target genes PGK and Glut-1 of cells growing at normoxia and hypoxia (Supplementary Figure 1B and C) .
To explore the effects of HIF-1a deletion in the VHL KO background on subcutaneous tumor growth, the VHL KO, HIF-1a/VHL KO and their WT control astrocytes were grown in the flanks of immunocompromized mice as described in Materials and methods. As is shown in Figure 1a loss of HIF-1a in the VHL background reduced tumor mass, although just to the border of significance (P ¼ 0.06). Hematoxylin and eosin analysis of these tumors revealed lack of hemangiomas ( Figure 1b) . Furthermore, the size and number of necrotic regions was similar and all the tumor types formed well-defined borders and did not metastasize to other organs (not shown). The vessel density was analysed as is described in Materials and methods. As shown in Figure 1c both the VHL KO and HIF-1a/VHL KO tumors displayed a 2.6-fold increase in vessel density compared to WT. Additional characteristics of increased angiogenesis or vascular lesions associated with VHL disease were not detected in the subcutaneous tumors.
VHL null-transformed astrocytes implanted in the brain form highly vascular tumors in a HIF-1a-dependent manner The lack of additional vascular lesions associated with loss of VHL in the subcutaneous tumor model made it difficult to establish the contribution of HIF-1a to the angiogenesis in tumors lacking VHL. Therefore, the cells were also implanted in the brain, which is their natural habitat and recapitulates the interactions between the tumor cells and natural environment, which are important for angiogenesis.
There was no significant difference in the survival of the mice between the VHL KO and HIF-1a/VHL KO tumor groups (Figure 2a , P ¼ 0.32). It was therefore surprising that the brain tumors derived from the VHL KO cells, displayed a striking HIF-1a-dependent increase in vascularity (Figure 2b-d) . Loss of VHL caused large hemangiomas in 90% of the brain tumors, which was reduced to 35% upon deletion of HIF-1a in this background (P ¼ 0.01 by w 2 test; Figure 2b ). Compared to the VHL KO, the vessel density was a 41% reduced, in the HIF-1a/VHL KO brain tumors (Figure 2c, lower panel) . Similarly, loss of VHL in the brain tumors causes a 25% increase in the percentage of proliferating endothelial cells compared to the WT controls, which was reduced to 7% upon loss of HIF-1a in this background (Figure 2d, lower panel) . Furthermore, vessels of the VHL KO brain tumors contained multiple nuclei that were positive for 5-bromodeoxyuridine (BrdU) (black arrow shown in upper center panel, Figure 2d ), indicating vessel hyperplasia which is associated with the vascular lesions in VHL disease (Hasselblatt et al., 2005) . This aspect of angiogenesis was also dependent on HIF-1a, as vessel hyperplasia was absent in the HIF-1a/VHL KO brain tumors (compare vessels indicated by black arrows in center -VHL KO and right-HIF-1a/VHL KO panels, Figure 2d ).
Vessel apoptosis is HIF-1a dependent in VHL KO cells grown in the brain It was reported that the increase in vascularity of subcutaneously growing tumors lacking pVHL was correlated with dysregulation of fibronectin assembly (Mack et al., 2003 (Mack et al., , 2005 Rathmell et al., 2004) . In an attempt to explain the site-specific contribution of HIF-1a to the angiogenesis of the VHL KO tumors, the cells and tumors were analysed for fibronectin expression and assembly. Fibronectin was not expressed in vitro in the transformed astrocytes (not shown). Immunohistochemical analysis showed reactivity of a-fibronectin with blood vessels (Supplementary Figure 2A and B), but did not reveal any difference in the expression level or assembly between the different tumor types grown in the different microenvironments. Similar data was found for laminin, another molecule involved in vessel maturation (Supplementary Figure 2C and D) .
Because angiogenesis is a result of the balance between endothelial cell proliferation and apoptosis (Bergers and Benjamin, 2003) we next analysed vessel apoptosis in the tumors as described in Materials and methods. In the subcutaneous tumors, only a small percentage of the vessels were apoptotic (6% for the WT, and 3% for the HIF-1a/VHL KO tumors, Figure  3a and b). In contrast, the percentage of apoptotic blood vessels was significantly increased in the brain tumors. This is particularly the case in the vessels of the HIF-1a/ VHL KO brain tumors that were co-opted by tumor cells, indicated by red arrows in lower panels of Figure 3a . Compared to the VHL KO tumors, the apoptotic rate of the vessels in the HIF-1a/VHL KO tumors was almost a fivefold increased (Figure 3b ). These data suggest that the reduced vascularization observed in the HIF-1a/VHL KO brain tumors results from increased blood vessel apoptosis owing to loss of HIF-1a.
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Expression of VEGF in VHL KO-transformed astrocytes is dependent on HIF-1a It has been shown by many studies that that tumor cell-secreted VEGF is a critical factor for vascular function (e.g., Grunstein et al., 1999) , and that loss of VEGF in tumors derived from a glioma cell line results in an increase in vessel apoptosis (Benjamin and Keshet, 1997) . Given the difference in vessel apoptosis between the HIF-1a/VHL KO tumors grown in the brain and subcutaneously, we asked whether the expression of VEGF in the VHL KO tumors might be dependent on the microenvironment.
As is shown in Figure 4a and b, there is a small but significant HIF-1a-dependent increase (P ¼ 0.05) in VEGF expression in the VHL KO cells growing under normoxia and hypoxia conditions or subcutaneously (respectively 1.5-, 2-, 2.3-fold). Similar values were obtained for the VHL KO brain tumor. These data were confirmed by immunofluorescence staining for VEGF of both subcutaneous and brain tumors ( Figure 4c ). Therefore, we conclude that in the VHL Loss of VEGF expression reduces vascularization B Blouw et al KO transformed astrocytes, VEGF expression is dependent on HIF-1a regardless of the microenvironment in which the cells are grown. These data suggest that VEGF is not the key factor in causing the different vascularity of the HIF-1a/VHL KO tumors growing in the brain versus subcutaneous site. 
Tumor vascularization of VHL KO-transformed astrocytes is dependent on VEGF Loss of VHL causes the up regulation of many growth factors, which may compensate for a reduction in VEGF expression, and allow tumor growth to occur (Kaelin, 2002) . To test whether the VHL KO tumor growth and vascularization was dependent on expression of tumor cell-derived VEGF, we next implanted astrocytes in which VEGF is deleted in the VHL KO background (VEGF/VHL KO) in the subcutis and brain. These cells were produced in the same way as the VHL KO and HIF-1a/VHL KO cell lines. As shown in Figure 5a , loss of VEGF in the VHL KO tumors decreases tumor growth by 63% compared to the VHL KO tumors (Po0.05). Surprisingly, when the same cells were grown in the brain, the survival was not altered compared to mice having the VHL KO brain tumors (Figure 6a , P ¼ 0.24). Figure 3 Vessel apoptosis is HIF-1a dependent in VHL KO astrocytes grown in the brain. (a) Vessel apoptosis was tested using a double stain for CD31 (green) and for Active Caspase 3 (red). Apoptotic vessels stain double for both CD31 and Active Caspase 3, as shown by the insets of the vessels indicated by the asterisks in the upper panels (inset is Â 600 magnification). Lower panels represent the double stain in the brain tumors, where also a background stain with DAPI was performed to indicate tumor cells co-opting the blood vessels. Red arrows point to co-opted vessels that are apoptotic, white arrows point to those that are not apoptotic. Magnifications are indicated; scale bar ¼ 100 mm. (b-c) Bar graphs showing the rate of apoptotic vessels in respectively the subcutaneous tumors (b) and the brain tumors (c). Apoptotic rate was determined as is described in Materials and methods. Columns, mean; error bars, 95% confidence intervals (Po0.05).
Independent of the implantation site however, the vascularity of the VHL tumors was dependent on VEGF. Compared to the VHL KO, the vessel density was reduced by 54% in the subcutaneous tumor, and by 47% in the brain tumor, respectively, upon loss of VEGF in the VHL KO background (Figures 5b, c and  6d ). In the subcutaneous site, vessels appeared necrotic (encircled area in Figure 5b , right panel). Along those lines, when compared to the VHL KO tumors, vessel apoptosis was increased approximately 10-fold in the subcutis, and fivefold in the brain tumors (Figures 5d, e and 6e). Endothelial cell proliferation was decreased in both sites (not shown). Further, loss of VEGF eradicated the appearance of large hemangiomas associated with loss of VHL in the brain tumors (Figure 6b and c) .
Taken together, our data indicates that VEGF is a critical factor in tumor angiogenesis associated with loss of pVHL, regardless of the microenvironment. Our data implies that even though inhibition of VEGF reduces tumor angiogenesis, it may not be sufficient to inhibit tumor growth in VHL disease.
Discussion
Determining the contribution of the HIF/VEGF pathway to the tumor growth and angiogenesis associated with loss of VHL is important for novel therapeutic approaches. In the well-studied VHL null cell line 786-O, HIF-1a is not expressed, and VEGF expression is mainly driven by HIF-2a (Carroll and Ashcroft, 2006) . However, in other tumor types associated with VHL disease such as hemangioblastoma, HIF-1a is overexpressed and correlates with the expression of VEGF (Flamme et al., 1998; Zagzag et al., 2000) . In addition, Loss of VEGF expression reduces vascularization B Blouw et al both HIF-1a and HIF-2a are expressed in lesions of the kidney in VHL disease (Mandriota et al., 2002) . These observations underscore the importance of understanding the relative contributions of each protein to different aspects in tumor formation associated with VHL disease.
In this work, we examined the contribution of HIF-1a and its target VEGF to tumor growth and angiogenesis upon loss of pVHL in a genetic mouse implantation model. Transformed astrocytes lacking pVHL alone or in combination with HIF-1a (HIF-1a/VHL KO), and VEGF (VEGF/VHL KO), were grown in heterotopic and orthotopic sites in mice. This model requires the transformation of primary cells that are obtained from the transgenic mice (in this work Simian virus 40 Large T and H-Ras), in order to generate tumor growth by these cells in vivo. Even though this may lead to side effects that potentially influence the growth proliferation of these cells unrelated to the deletion of the specific gene, this method is frequently used when investigating the role of a particular gene during tumor growth in vivo using primary mouse cells (Ryan et al., 2000; Unruh et al., 2003; Mack et al., 2005) . We primarily chose this model because it was shown to recapitulate relevant tumor-host interactions in the orthotopic settings important for angiogenesis (Blouw et al., 2003) .
We report astrocytoma cells lacking pVHL implanted subcutaneously formed tumors with an increased vessel density, but that additional vascular lesions associated with loss of pVHL were not observed (Kaelin, 2002) . This result is consistent with what has been reported for subcutaneously growing fibrosarcomas lacking pVHL (Mack et al., 2005) . Possibly, cells must grow in a highly vascular environment in order to recapitulate the vascular features in tumors associated with loss of pVHL. This is supported by our model, where loss of pVHL in transformed astrocytes formed a highly angiogenic tumor type when grown in the brain, with a vessel pathology that resembled that of human hemangioblastoma (Hasselblatt et al., 2005; Hansel, 2006) .
In our model, the contribution of HIF-1a to the vascularization of astrocytomas lacking pVHL was dependent on the microenvironment. Compared to the 
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WT control tumors, the vessel density was increased in both the VHL KO and HIF-1a/VHL KO subcutaneous tumors. In the brain, the vascularization of the HIF-1a/ VHL KO tumors was reduced when compared to VHL KO tumors. These data did not correlate with the expression of VEGF; irrespective of the microenvironment, loss of HIF-1a in the VHL KO background reduced the expression of VEGF. This is consistent with reports of mouse embryo fibroblasts and MCF7 cells, that show a HIF-1a-dependent increase expression of VEGF upon hypoxia exposure (Ryan et al., 2000; Mack et al., 2005; Carroll and Ashcroft, 2006) . We did not detect differences in HIF-2a expression in the astrocytes under hypoxia or normoxia (not shown) (Blouw et al., 2003) . In a conditional mouse model where pVHL is deleted in the kidney and liver, VEGF expression in these tissues was dependent on intact HIF signaling (Rankin et al., 2005) . This indicates that the contribution of either HIF-1a or HIF-2a, or both, to the expression of VEGF and angiogenesis might depend on the different tumor types associated with VHL disease. The angiogenesis of the VHL KO astrocytoma depends on the expression of tumor cell-derived VEGF. Loss of VEGF in the VHL KO background causes hemangiomas to disappear, combined with a striking increase in vessel apoptosis in both the subcutaneous and brain tumors. This correlated with a reduction in tumor growth only in the subcutaneous site. Although the orthotopic tumor growth is measured by the survival of the mice, which may be an outcome of both tumor formation and edema, and may not necessarily reflect tumor growth alone, we previously reported that deletion of VEGF in transformed astrocytes reduced tumor growth independent of the implantation site (Blouw et al., 2003) . This apparent discrepancy can be explained by studies showing that loss of pVHL causes the upregulation of genes that are important in angiogenesis and invasion, such as CXCR4, SDF-1 (Staller et al., 2003; Zagzag et al., 2005) , matrix metalloproteinases 2 and 9, the Met receptor (Koochekpour et al., 1999) and components of the urokinase plasminogen activator pathway (Los et al., 1999) . Consistent with these observations, the VEGF/VHL KO astrocytes were capable of invading different parts of the brain when grown intracranially (not shown). This indicates that although loss of VEGF in the VHL KO background reduces tumor angiogenesis, the upregulation of other proinvasive and proangiogenic factors may compensate, and be sufficient to sustain tumor growth and tumor cell survival.
Tumors that arise in VHL disease are in general benign and have a low metastatic rate. The treatment is often surgical removal of the tumor (Lonser et al., 2003) . Nevertheless, many patients still develop severe disease complications, such as blindness or brain damage. Therefore it has been proposed that a VEGF blockade could be of great value to patients with VHL syndrome (Harris, 2000) . Since that time, clinical trials have been carried out with various angiogenesis inhibitors (Staehler et al., 2005) . Our data supports the idea exploring antiangiogenesis therapeutics for this disease; but suggests that this could be strongly influenced by the tissue in which the disease is manifesting itself.
Materials and methods
Generation of VHL KO-, HIF-1a/VHL KO-and VEGF/VHL KO-transformed astrocytes Primary astrocytes were isolated from 1 to 2-day-old pups that were homozygous for either VHL þ f/ þ f alone, or in combination with (Ryan et al., 1998; Gerber et al., 1999; Haase et al., 2001) . From these cells, stably transformed cell lines were created that lacked the floxed alleles as described in Blouw et al. (2003) . The WT or null status was confirmed as described in Tang et al. (2006) . HIF-1a expression and target gene upregulation was carried out according to Seagroves et al. (2003) .
Tissue culture Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% Penicillin/ Streptomycin, 1% sodium pyruvate and 1% N-2-hydroxyethylpiperazine-N 0 -2-ethanesulphonic acid (Invitrogen, Carlsbad, CA, USA) all in a standard humidified incubator with pO 2 20% and CO 2 5%. For the hypoxia treatment cells were transferred to a hypoxia chamber (Sanyo, Bensenville, IL, USA) and cultured for 6 h at pO 2 0.5%.
Tumor implantation experiments
All tumor implantation experiments were performed on nu/nu mice at 4-6 weeks of age (Simonsen Laboratory, San Jose, CA, USA). For the subcutaneous implantation, 3 Â 10 6 cells in 100 ml phosphate-buffered saline were grown in the flank of the mice (10-13 mice per group) for 21 days. The intracranial implantation, was carried according to Blouw et al. (2003) . RNA was extracted from 3 to 5 tumors per group and VEGF expression was tested according to Tang et al. (2004) .
Histological analysis
Sections were stained with anti-rat CD31 primary antibody (Pharmigen BD Biosciences, San Jose, CA, USA) followed by a fluorescein isothiocyanate-conjugated anti-rat secondary antibody (Pierce, Rockford, IL, USA). Vessel density was calculated using ImageJ software analysis of photographs taken with the Â 20 objective of five randomly chosen fields from seven tumors per group and expressed as number of vessels per mm 2 . Endothelial cell proliferation was visualized and calculated as described in Tang et al. (2004) . Sections were stained for CD31 as is described above and with anti-rabbit Active Caspase 3 primary antibody (R&D Systems, Minneapolis, MN, USA) followed by Alexa Fluor 555 secondary antirabbit (Invitrogen, Carlsbad, CA, USA). Vessel apoptosis was determined by calculating the ratio of vessels that stained for both CD31 and Caspase 3 per total number of vessels per mm 2 from pictures taken with the Â 20 objective of five randomly chosen fields from seven tumors per group. Sections were stained with goat anti-mouse VEGF (R&D Systems, Minneapolis, MN, USA) followed by Texas Red conjugated antimouse secondary antibody (Invitrogen, Carlsbad, CA, USA), with rabbit a-fibronectin, and rabbit a-laminin (both Sigma, St Louis, MO, USA) respectively. Both were followed by a secondary antibody biotinylated anti-rabbit (Vectorlabs, Burlingame, CA, USA). The magnifications of the photographs of the histology are indicated in each figure.
Statistical analysis
Results are expressed as mean values with 95% confidence interval. Unless otherwise noted, the statistical significance of differences between experimental and control groups was determined by a two-tailed unpaired Student's t-test. P-values less or equal to 0.05 are considered statistically significant.
